**Supplementary Table 4.** The AEs in different regimens

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| AEs (n/N)**＆** | DCV/ASV%, (95% CI) | PrOD ± RBV%, (95% CI) | EBR/GZR%,(95% CI) | SOF/LDV±RBV%, (95% CI) | SOF/RBV%, (95% CI） | SOF/DCV±RBV%, (95% CI) | GLE/PIB%, (95% CI) | SOF/VEL±RBV%, (95% CI) |
| Any AEs(2,208/14,547) | 11.9, (10.6-13.3) | 22.8, (20.5-25.1) | 10.9, (8.7-13.3) | 10.0,(9.1-10.9) | 22.6, (21.1-24.3) | 34.0,(29.0-39.3) | 23.1, (20.7-25.8) | 7.9,(6.6-9.4) |
| AEs |
| Fatigue (787/14,229) | 2.6,(2.0-3.4) | 8.0,(6.6-9.6) | 5.7,(4.0-7.7) | 4.2,(3.7-4.9) | 7.2(6.2-8.2) | 15.5,(11.9-19.9) | 11.8, (9.8-14.1) | 2.1,(1.4-2.9) |
| Nausea(215/14,240)  | 0.9,(0.6-1.4) | 2.3,(1.5-3.2) | 1.6,(0.8-2.8) | 0.7,(0.5-1.0) | 2.0,(1.5-2.6) | 4.7,(2.7-7.5) | 2.8,(1.9-4.1) | 1.3,(0.8-2.0) |
| Pruritus (391/14,226) | 0.9,(0.6-1.4) | 9.4,(7.9-11.2) | 1.6,(0.8-2.8) | 0.9,(0.6-1.2) | 2.9,(2.3-3.6) | 3.8,(2.0-6.4) | 9.2,(7.4-11.3) | 0.9,(0.5-1.5) |
| Headache (258/14,112) | 0.9,(0.6-1.4) | 0.7,(0.3-1.4) | 1.6,(0.7-2.6) | 2.2,(1.8-2.7) | 1.6,(1.2-2.2) | 5.0,(2.9-7.9) | 3.5,(2.4-4.8) | 1.3,(0.8-2.0) |
| Insomnia (271/14,232) | 0.9,(0.6-1.4) | 6.9,(5.6-8.4) | 1.3,(0.6-2.4) | 1.0,(0.7-1.3) | 1.7,(1.3-2.3) | 7.6,(5.0-11.0) | 2.1,(1.3-3.2) | 0.7,(0.3-1.3) |
| Vomiting(4/10,034) | 0,(0-0.2)\* | 0,(0-0.4)\* | 0,(0-0.5)\* | 0.1,(0-0.2) | 0.1,(0-0.3) | 0,(0-1.4)\* | 0,(0-0.3)\* | 0.06,(0-0.3) |
| Hypertensive(5/10,038) | 0.2,(0-0.6) | 0,(0-0.4)\* | 0.1,(0-0.8) | 0,(0-0.1)\* | 0,(0-0.2)\* | 0,(0-1.4)\* | 0.1,(0-0.5) | 0,(0-0.2)\* |
| Depression(13/10,039) | 0.2, (0-0.6) | 0.1,(0-0.7) | 0,(0-0.5)\* | 0,(0-0.1)\* | 0,(0-0.5) | 0,(0-1.4)\* | 0.5,(0.1-1.2) | 0,(0-0.2)\* |
| Jaundice(7/10,038) | 0,(0-0.2)\* | 0.5,(0.1-1.3) | 0.1,(0-0.8) | 0,(0-0.1)\* | 0,(0-0.2)\* | 0,(0-1.4)\* | 0,(0-0.3)\* | 0.1,(0-0.3) |
| Treatment discontinuation(319/14,629) | 6.4,(5.4-7.4) | 3.2,(2.3-4.2) | 1.3,(0.6-2.3) | 0.9,(0.6-1.2) | 1.3,(0.9-1.8) | 0.5,(0-1.9) | 2.2,(1.3-3.1) | 0.9,(0.5-1.5) |
| Deaths(125/14,326) | 1.1,(0.7-1.6) | 0.7,(0.4-1.3) | 0.6,(0.2-1.4) | 0.9,(0.6-1.2) | 0.5,(0.3-0.9) | 1.5,(0.5-3.6) | 0.5,(0.2-1.2) | 1.0,(0.3-2.2) |

\*one-sided, 97.5% confidence interval. **＆**(n/N): Number of adverse events/number of assessable patients. AEs, Adverse events; SOF, Sofosbuvir; VEL, Velpatasvir; RBV, Ribavirin; DCV, Daclatasvir; ASV, Asunaprevir; LDV, Ledipasvir; PrOD, Paritaprevir/ritonavir, ombitasvir + dasabuvir; EBR, Elbasvir; GZR, Grazoprevir; GLE, Glecaprevir; PIB, Pibrentasvir; CI, Confidence interval.